Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 4, 2003, Pages 576-581

  Gavin, Patrick J ^a,b   Crawford, Susan E ^b   Shulman, Stanford T ^a,b   Garcia, Francesca L ^b   Rowley, Anne H ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Aneurysm; Coronary artery; Kawasaki disease; Matrix metalloproteinases

Indexed keywords

ELASTIN; GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANGIOGENESIS; ARTERY INTIMA; ARTERY WALL; ARTICLE; CAPILLARY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY ANEURYSM; ENDOTHELIUM CELL; FATALITY; HEART NERVE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; INFECTION; INFLAMMATION; MESENTERIC ARTERY; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENAL ARTERY; SYSTEMIC CIRCULATION;

ACUTE DISEASE; CHILD; CORONARY ANEURYSM; CORONARY VESSELS; ELASTIN; ENZYME INDUCTION; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MUCOCUTANEOUS LYMPH NODE SYNDROME; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUNICA INTIMA;

EID: 0037388982     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000065385.47152.FD     Document Type: Article

References (21)

1. Rowley AH, Shulman ST. Kawasaki syndrome. Pediatr Clin North Am. 1999:46:313-329.
2. Taubert KA, Rowley AH, Shulman ST. Nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr. 1991;119:279-282.
3. Kato H, Inoue O, Akagi T. Kawasaki disease: cardiac problems and management. Pediatr Rev. 1988:9:209-217.
4. Fujiwara H, Hamashima Y. Pathology of the heart in Kawasaki disease. Pediatrics. 1978;61:100-107.
5. Amano S, Hazama F. Hamashima Y, Pathology of Kawasaki disease: pathology and morphogenesis of the vascular changes. Jpn Circ J. 1979;43:633-643.
6. Parsons SL, Watson SA, Brown PD. Collins HM. Steele RJC. Matrix metalloproteinases. Br J Surg. 1997;84:160-166,
7. Longo GM, Xiong W, Greiner TC. Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest. 2002;110:625-632.
8. Thompson RW, Holmes DR, Mertens RA, Liao S. Botney MD, Mecham RP, Welgus HG, Parks WC. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. J Clin Invest. 1995;96:318-326.
9. Suzuki A, Miyagawa-Tomita S, Komatsu K, Nishikawa T, Sakomura Y, Horie T, Nakazawa M. Active remodeling of the coronary artery lesions in the late phase of Kawasaki disease. Circulation. 2000;101:2935-2941.
10. Herron GS, Unemori E, Wong M, Rapp JH, Hibbs MH, Stoney RJ. Connective tissue proteinases and inhibitors in abdominal aortic aneurysms. Arterioscler Thromb. 1991;11:1667-1677.
11. Amano S, Hazama F, Hamashima Y. Pathology of Kawasaki disease: distribution and incidence of the vascular lesions. Jpn Circ J. 1979;43:741-748.
12. Robinson SC, Scott KA, Balkwill FR. Chemokine stimulation of monocyte matrix metallproteinase-9 requires endogenous TNF-α. Eur J Immunol. 2002;32:404-412.
13. Lin CY, Lin CC, Hwang B, Chiang B. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor-α among patients with Kawasaki disease. J Pediatr. 1992;121:924-926.
14. Maury CPJ, Salo E, Pelkonen P. Elevated circulating tumor necrosis factor-α in patients with Kawasaki disease. J Lab Clin Med. 1989;113:651-654.
15. Khan KMF, Falcone DJ, Kraemer R. Nerve growth factor activation of Erk-1 and Erk-2 induces matrix metalloproteinase-9 expression in vascular smooth muscle cells. J Biol Chem. 2002;277:2353-2359.
16. Falcini F, Cerinic MM, Ermini M, Generini S, Lombardi A, Pignone A, Leoncini G, Tirassa P, Aloe L. Nerve growth factor circulatinglevels are increased in Kawasaki disease: correlation with disease activity and reduced angiotensin converting enzyme levels. J Rheumatol. 1996;23:1798-1802.
17. Takeshita H, Yoshizaki T, Miller WE, Sato H, Furukawa M, Pagano JS, Raab-Traub N. Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J Virol. 1999:73:5548-5555.
18. Yeo SJ. Kim SJ, Kim JH, Lee HJ, Kook YH. Influenza A virus infection modulates the expression of type IV collagenase in epithelial cells. Arch Virol. 1999;144:1361-1370.
19. Mori N, Sato H, Hayashibara T, Senba M, Hayashi T, Yamada Y, Kamihira S, Ikeda S, Yamasaki Y, Morikawa S, Tomonaga M, Geleziunas R, Yamamoto N. Human T-cell leukemia virus type I Tax transactivated the matrix metalloproteinase-9 gene: potential role in mediating adult T-cell leukemia invasiveness. Blood. 2002;99:1341-1349.
20. Yeo SJ, Yun YJ. Lyu MA. Woo SY, Woo ER. Kim SJ, Lee HJ, Park HK, Kook YH. Respiratory syncytial virus infection induces matrix metalloproteinase-9 expression in epithelial cells. Arch Virol. 2002;147:229-242.
21. Quiding-Jarbrink M, Smith DA, Bancroft GJ. Production of matrix metalloproteinases in response to mycobacterial infection. Infect Immun. 2001;69:5661-5670.